1-5 of 5
Shuailing Peng
Close
Sort by
Journal Articles

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6227.
https://doi.org/10.1182/blood-2023-184694
Published: 2023
Journal Articles

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6242.
https://doi.org/10.1182/blood-2023-184634
Published: 2023
Journal Articles

Updated Results of a Prospective Study: Rituximab and Lenalidomide Plus Chidamide (RLC) for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Cong Li, Huixian HU, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han, Haiyan Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6221.
https://doi.org/10.1182/blood-2023-184830
Published: 2023
Journal Articles

Rituximab and Lenalidomide Plus Chidamide Can be an Effective Chemotherapy Regimen for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma

Cong Li, Tao Lei, Haifeng Yu, Xi Chen, Shuiyun Han, Shuailing Peng, Haiyan Yang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3689–3690.
https://doi.org/10.1182/blood-2022-166370
Published: 2022
Journal Articles

"Gentle Initiation” Rituximab, Lenalidomide and Zanubrutinib Chemo-Free Regimen Followed By Immunochemotherapy for Elderly/Frail Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Investigator Initiated, Single Arm, Phase 2 Trial

Xi Chen, Tao Lei, Haifeng Yu, Cong Li, Shuiyun Han, Shuailing Peng, Haiyan Yang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9452–9453.
https://doi.org/10.1182/blood-2022-164486
Published: 2022